Rehospitalization Risk of Receptor-Affinity Profile in Antipsychotic Drug Treatment: A Propensity Score Matching Analysis Using a Japanese Employment-Based Health Insurance Database

References

• Ministry of Health, Labour and Welfare [homepage on the Internet]. [Websites on mental health, illness, support and services. Schizophrenia]. Available from: http://www.mhlw.go.jp/kokoro/speciality/detail_into.html. Accessed 71, 2020.
   Google Scholar
• Uchiyama N, Ikeno T, Kurihara T, et al. Predictive factors of readmission in patients with schizophrenia: a nationwide retrospective cohort study. Clin Psychiatry. 2012;54:1201–1207.
   Google Scholar
• Shimada T, Nishi A, Yoshida T, Tanaka S, Kobayashi M. Factors Influencing Rehospitalisation of Patients with Schizophrenia in Japan: A 1-year Longitudinal Study. Hong Kong J Occup Ther. 2016;28(1):7–14. doi:10.1016/j.hkjot.2016.10.00230186062
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886–891. doi:10.1176/appi.ps.55.8.88615292538
   PubMed Web of Science ®Google Scholar
• Greene M, Yan T, Chang E, Hartry A, Touya M, Broder MS. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2018;21(2):127–134. doi:10.1080/13696998.2017.137941228895758
   PubMed Web of Science ®Google Scholar
• Velligan DI, Sajatovic M, Hatch A, Kramata P, Docherty JP. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11:449–468. doi:10.2147/PPA.S12465828424542
   PubMed Web of Science ®Google Scholar
• Hatano M, Kamei H, Kato A, et al. Assessment of the Latent Adverse Events of Antipsychotic Treatment Using a Subjective Questionnaire in Japanese Patients with Schizophrenia. Clin Psychopharmacol Neurosci. 2017;15(2):132–137. doi:10.9758/cpn.2017.15.2.13228449560
   PubMed Web of Science ®Google Scholar
• Afonso P, Brissos S, Cañas F, Bobes J, Bernardo-Fernandez I. Treatment adherence and quality of sleep in schizophrenia outpatients. Int J Psychiatry Clin Pract. 2014;18(1):70–76. doi:10.3109/13651501.2013.84521924047426
   PubMed Web of Science ®Google Scholar
• Berardis DD, Rapini G, Olivieri L, et al. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Therapeutic Advances in Drug Safety. 2018;9(5):237–256. doi:10.1177/204209861875626129796248
   PubMed Web of Science ®Google Scholar
• Orsolinia L, Tomasetti C, Valchera A, et al. An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf. 2016;15(10):1329–1347. doi:10.1080/14740338.2016.120147527347638
   PubMed Web of Science ®Google Scholar
• Orsolinia L, Berardis DD, Volpe U. Up-to-date expert opinion on the safety of recently developed antipsychotics. Expert Opin Drug Saf. 2020;19(8):981–997. doi:10.1080/14740338.2020.179512632657173
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Xu J, Sarma K, Pikalov A, Kane JM. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res. 2013;147(1):95–102. doi:10.1016/j.schres.2013.03.01323583011
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80mg/day and 160mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013;145(1–3):101–109. doi:10.1016/j.schres.2013.01.00923415311
   PubMed Web of Science ®Google Scholar
• Sunovion [homepage on the Internet]. Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia (PEARL 3 Ext); 2012 Available from: https://clinicaltrials.gov/ct2/show/NCT00789698. Accessed 71, 2020.
   Google Scholar
• Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25(Suppl S2):S12–S21. doi:10.1016/S0924-9338(10)71701-620620881
   PubMed Web of Science ®Google Scholar
• Murasaki M, Nishikawa H, Ishibashi T. [Dopamine-serotonin antagonist: receptor binding profile of a novel antipsychotic blonanserin]. Jpn J Clin Psychopharmacol. 2008;11:845–854.
   Google Scholar
• Gray JA, Roth BL. The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007;12(10):904–922.17667958
   PubMed Web of Science ®Google Scholar
• JMDC Inc. [homepage on the Internet]. Available from: https://www.jmdc.co.jp/. Accessed 520, 2020.
   Google Scholar
• Limosin F, Belhadi D, Comet D, et al. Comparison of Paliperidone Palmitate and Risperidone Long-Acting Injection in Schizophrenic Patients: results From a Multicenter Retrospective Cohort Study in France. J Clin Psychopharmacol. 2018;38(1):19–26. doi:10.1097/JCP.000000000000082729232310
   PubMed Web of Science ®Google Scholar
• Lafeuille M-H, Laliberté-Auger F, Lefebvre P, Frois C, Fastenau J, Duh MS. Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry. 2013;13(1):221. doi:10.1186/1471-244X-13-22124016390
   PubMed Web of Science ®Google Scholar
• Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M. Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia. Am J Psychiatry. 2016;173(2):166–173. doi:10.1176/appi.ajp.2015.1503033226541815
   PubMed Web of Science ®Google Scholar
• Lafeuille M-H, Grittner AM, Fortier J, et al. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics. Am J Health Syst Pharm. 2015;72(5):378–389. doi:10.2146/ajhp14021925694413
   PubMed Web of Science ®Google Scholar
• Pilon D, Amos TB, Germain G, Lafeuille M-H, Lefebvre P, Benson CJ. Treatment persistence and hospitalization rates among patients with schizophrenia: a quasi-experiment to evaluate a patient information program. Curr Med Res Opin. 2017;33(4):713–721. doi:10.1080/03007995.2016.127798928055336
   PubMed Web of Science ®Google Scholar
• MacEwan JP, Kamat SA, Duffy RA, et al. Hospital Readmission Rates Among Patients With Schizophrenia Treated With Long-Acting Injectables or Oral Antipsychotics. Psychiatr Serv. 2016;67(11):1183–1188. doi:10.1176/appi.ps.20150045527417897
   PubMed Web of Science ®Google Scholar
• Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21(1):128–138. doi:10.1097/EDE.0b013e3181c30fb220010215
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Labour and Welfare [homepage on the Internet]. [4th NDB Open Data Japan]. Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000177221_00003.html. Accessed 71, 2020.
   Google Scholar